Understanding the cardiovascular risk with non-insulin antidiabetic drugs

Expert Opinion on Drug Safety
Vasilios G AthyrosMichael Doumas

Abstract

Diabetes mellitus is a major public health problem with significant macro- and microvascular complications. Achievement of glucose control is associated with a substantial reduction of microvascular events, while the effects of antidiabetic drugs in macro-vascular complications are less clear. This review summarizes and critically discusses the cardiovascular effects of non-insulin antidiabetic agents. A selective literature search of Pubmed was performed regarding the efficacy and safety of non-insulin antidiabetic agents in randomized controlled clinical trials and relevant meta-analyses. Data are presented for all major classes of antidiabetic drugs: metformin, sulfonylureas, thiazolidinediones, DPP-4 inhibitors, GLP-1 analogues, and SGLT-2 inhibitors. Efficacy and safety were focused on the cardiovascular system. Disparities in cardiovascular safety and efficacy between antidiabetic drugs exist. Metformin remains the first-choice drug with proven cardiovascular benefits. The cardiovascular profile of sulfonylureas is yet unclarified, while thiazolidinediones seem to be effective in secondary stroke prevention but heart failure concerns limit their use. The cardiovascular safety of DPP-4 inhibitors has been demonstrated, wit...Continue Reading

References

Jan 18, 2006·CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne·Scot H SimpsonJeffrey A Johnson
May 23, 2007·The New England Journal of Medicine·Steven E Nissen, Kathy Wolski
Aug 8, 2007·Annals of Internal Medicine·George A DiamondSanjay Kaul
Sep 13, 2007·JAMA : the Journal of the American Medical Association·Sonal SinghCurt D Furberg
Jun 10, 2008·The New England Journal of Medicine·Anushka PatelFlorence Travert
Jun 10, 2008·The New England Journal of Medicine·UNKNOWN Action to Control Cardiovascular Risk in Diabetes Study GroupWilliam T Friedewald
Sep 12, 2008·The New England Journal of Medicine·Rury R HolmanH Andrew W Neil
Oct 3, 2009·Diabetes Research and Clinical Practice·Mykola KhalangotVladimir Kovtun
Apr 19, 2013·Diabetes, Obesity & Metabolism·M MonamiE Mannucci
May 15, 2013·Diabetic Medicine : a Journal of the British Diabetic Association·O J PhungS N Rajpathak
Aug 21, 2013·Diabetes/metabolism Research and Reviews·Yi-Chih HungChing-Chu Chen
Sep 3, 2013·The New England Journal of Medicine·Benjamin M SciricaUNKNOWN SAVOR-TIMI 53 Steering Committee and Investigators
Sep 3, 2013·The New England Journal of Medicine·William B WhiteUNKNOWN EXAMINE Investigators
Sep 13, 2013·Annals of Internal Medicine·Despoina VasilakouApostolos Tsapas
Sep 23, 2014·The New England Journal of Medicine·Sophia ZoungasUNKNOWN ADVANCE-ON Collaborative Group
Dec 4, 2014·The Lancet. Diabetes & Endocrinology·Scot H SimpsonTravis R Featherstone
Mar 18, 2015·Diabetes & Vascular Disease Research : Official Journal of the International Society of Diabetes and Vascular Disease·Nikolaus MarxHans-Juergen Woerle
Jun 9, 2015·The New England Journal of Medicine·Jennifer B GreenUNKNOWN TECOS Study Group
Sep 16, 2015·Journal of Hypertension·Konstantinos P ImprialosAsterios I Karagiannis
Sep 18, 2015·The New England Journal of Medicine·Bernard ZinmanUNKNOWN EMPA-REG OUTCOME Investigators
Dec 3, 2015·The New England Journal of Medicine·Marc A PfefferUNKNOWN ELIXA Investigators

❮ Previous
Next ❯

Citations

May 1, 2021·Advanced Healthcare Materials·Jinyuan ZhangChi Hwan Lee

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.